Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated at StockNews.com

Research analysts at StockNews.com began coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a research note issued on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Stock Performance

NASDAQ GLMD opened at $1.84 on Tuesday. The company has a market capitalization of $1.19 million, a P/E ratio of -0.11 and a beta of 0.66. The company has a fifty day moving average of $2.74 and a 200-day moving average of $3.55. Galmed Pharmaceuticals has a 52-week low of $1.75 and a 52-week high of $23.80.

Institutional Trading of Galmed Pharmaceuticals

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC purchased a new position in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned about 3.97% of Galmed Pharmaceuticals as of its most recent SEC filing. Institutional investors own 76.14% of the company’s stock.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.